Beyond mRNA - how advances in analytical techniques are enabling a revolution of the RNA drug landscape

Currently, there are three main types of in vitro transcribed (IVT) RNA drugs: conventional, non-replicating mRNA; base-modified, non-replicating mRNA (bmRNA), which incorporate chemically modified nucleotides; and self-replicating RNA (srRNA), based on an engineered viral genome but devoid of viral structural protein genes.

The ability to create copies of the drug after administration enables lower dosing and expands the range of potential indications. However, srRNAs are often much larger in size (9,000-16,000 bases) and traditional biophysical analytical techniques, such as capillary electrophoresis (CE), have been challenging to adapt to these large molecules.

This presentation will showcase how to achieve improved characterization of srRNA using the newest advances in CE. Additionally, we will discuss how these complement and augment in vitro cell-based assays currently being used for potency testing.

• Learn about the potential of srRNA as a vaccine and therapeutic modality
• Explore how advances in CE can overcome analytical difficulties when assessing RNA up to 16,000 bases
• Hear about how cell-based potency assays correlate with purity and size assessment with capillary gel electrophoresis

Andrew Geall

Chief Development Officer and Co-Founder at Replicate Bioscience

Dr Andrew Geall has over 20 years of professional experience in the development of drug delivery systems and is a pioneer in the fields of in vitro transcribed (IVT) RNA vaccines and nucleic acid delivery. He is an inventor on 41 patent families, with 505 applications and 203 issued patents in multiple jurisdictions.

Prior to joining Replicate, Andrew held multiple leading positions at Novartis, Avidity Biosciences and Precision NanoSystems Inc. (PNI) focusing on mRNA vaccines, siRNA, formulation, antibody-oligonucleotide conjugate delivery and nanoparticle drugs. In addition, he was Principal Investigator on a Defense Advanced Research Project Agency (DARPA) contract to develop self-replicating RNA vaccines.

Andrew received his pharmacy degree from the University of Bath in the UK and obtained his PhD at the University of Bath in non-viral gene delivery.

Watch now

SPEAKERS

Andrew Geall

Chief Development Officer and Co-Founder at Replicate Bioscience

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 58

Days

Register

Quadplex dPCR as a tool to analyze genome integrity and heterogeneity in gene therapy drug products

Ryan Massopust

11 June

in 42

Days

Register

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

6 June

in 37

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

Y Brudno, O Veiseh, M Delic-Schlumbohm et al.

5 June

in 36

Days

Register

Creating a closed-process, semi-automated workflow for human MSC expansion, harvest, and final fill

Julien Muzard, Donnie Beers

30 May

in 30

Days

Register